Improving the Efficacy of Anti-Nicotine Immunotherapy
NCT01280968
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
52
Enrollment
OTHER
Sponsor class
Conditions
Nicotine Dependence
Interventions
BIOLOGICAL:
NIC002 in Aluminum hydroxide (Alum)
BIOLOGICAL:
Placebo Vaccine - Aluminum hydroxide
Sponsor
Alexey Mukhin
Collaborators
[object Object]
[object Object]